ĐẶC ĐIỂM PHÂN BỐ VÀ TÍNH KHÁNG KHÁNG SINH CỦA PSEUDOMONAS AERUGINOSA TẠI BỆNH VIỆN NGUYỄN TRI PHƯƠNG GIAI ĐOẠN 2020 - 2023

Abstract

Introduction: Antibiotic resistance of Gram-negative strains of bacteria, including Pseudomonas aerugiosa, is increasingly complex. Understanding the microbiological characteristics of P. aeruginosa supports infection control and antibiotic use in hospitals. Objectives: To characterize the distribution and tendency to change antibiotic resistance of P. aeruginosa strains circulating at Nguyen Tri Phuong Hospital in the period of 2020 – 2023. Subjects and methods: the study describes a series of cases on P. aeruginosa strains isolated from patients treated at Nguyen Tri Phuong Hospital from January 2020 to December 2023. Differences in antibiotic resistance tendencies are examined using Chi squared. Results: During the study period, 940 specimens were isolated as P. aeruginosa, most concentrated in internal medicine departments (58.4%); In which, the highest proportion of specimens were respiratory specimens (48.9%), and purulent/exudate/catheter specimens (34.3%). After four years, P. Aeruginosa remains nearly completely sensitive to Colistin and exhibits resistance below 50% to most of the tested antibiotics include: carbapenem (imipenem 24.5%), 3.4th generation cephalosporins (cefepime 24.4%, ceftazidime 22.5%), aminoglycosides (amikacin 21.0%, gentamicin 27.4%; tobramycin 25.7%, netilmicin 22.6%) and piperacilin +tazobactam 10.9%. The antibiotic resistance rate of P. aeruginosa in clinical departments after four years was similar to the hospital-wide model, except that the ICU had significantly higher resistance rates than other departments to most antibiotics. The trend toward antibiotic resistance of P. aeruginosa has increased significantly with the majority of antibiotic trials. Conclusions: P. Aeruginosa remains 100% sensitive to Colistin and shows resistance below 50% to the majority of tested antibiotics. There is an increasing trend in resistance to antibiotics such as ciprofloxacin, cefepime, imipenem, piperacillin+tazobactam, and tobramycin. Controlled use of antibiotics is necessary in treating infections caused by this bacterium.